| |
RTX 500 mg × 2
|
RTX 1000 mg × 2
|
Unadjusted p values (ANOVA)
|
Adjusted p values**
|
|---|
|
DAS28 baseline
|
5.7 ± 1.3 (215)
|
6.1 ± 1.3 (2069)
|
<0.0001
| |
|
DAS28 3 m
|
4.4 ± 1.2 (138)
|
4.2 ± 1.3 (1046)
|
0.15
| |
|
DAS28 6 m
|
4.3 ± 1.3 (109)
|
4.3 ± 1.2 (1385)
|
0.99
| |
|
DeltaDAS28 3 m
|
–1.3 ± 1.3 (125)
|
–1.9 ± 1.4 (991)
|
<0.0001
|
0.004
|
|
DeltaDAS28 6 m
|
–1.7 ± 1.4 (100)
|
–2.0 ± 1.3 (1344)
|
0.02
|
0.23
|
|
HAQ baseline
|
1.6 ± 0.7 (212)
|
1.6 ± 0.7 (1584)
|
0.48
| |
|
HAQ 3 m
|
1.3 ± 0.7 (127)
|
1.3 ± 0.7 (957)
|
0.83
| |
|
HAQ 6 m
|
1.2 ± 0.7 (109)
|
1.3 ± 0.7 (912)
|
0.21
| |
|
DeltaHAQ 3 m
|
–0.3 ± 0.5 (115)
|
–0.5 ± 0.6 (859)
|
0.02
|
0.10
|
|
DeltaHAQ 6 m
|
-0.4 ± 0.6 (103)
|
–0.5 ± 0.7 (826)
|
0.13
|
0.27
|
- Crude and adjusted p valued are presented. **Analysis of covariance (ANCOVA) adjusted for age, sex, disease duration, number of prior biologic agents used, baseline Disease Activity Score in 28 joints (DAS28), concomitant use of disease-modifying anti-rheumatic drugs and glucocorticoids. RTX rituximab, HAQ Health Assessment Questionnaire, m months
